Sanofi Net Long-Term Debt 2010-2024 | SNY
Sanofi annual/quarterly net long-term debt history and growth rate from 2010 to 2024. Net long-term debt can be defined as the net amount of long term debt issued and repaid. This field is either calculated as the sum of the long term debt fields or used if a company does not report debt issued and repaid separately
- Sanofi net long-term debt for the quarter ending December 31, 2024 was $-0.726B, a 81.55% decline year-over-year.
- Sanofi net long-term debt for the twelve months ending December 31, 2024 was $-1.412B, a 79.41% decline year-over-year.
- Sanofi annual net long-term debt for 2024 was $-0.726B, a 81.55% decline from 2023.
- Sanofi annual net long-term debt for 2023 was $-3.935B, a 219.51% increase from 2022.
- Sanofi annual net long-term debt for 2022 was $-1.232B, a 53.55% decline from 2021.
Sanofi Annual Net Long-Term Debt
(Millions of US $) |
| 2024 |
$-726 |
| 2023 |
$-3,935 |
| 2022 |
$-1,232 |
| 2021 |
$-2,651 |
| 2020 |
$-2,208 |
| 2019 |
$-78 |
| 2018 |
$10,499 |
| 2017 |
$-2,630 |
| 2016 |
$2,431 |
| 2015 |
$1,716 |
| 2014 |
$-69 |
| 2013 |
$395 |
| 2012 |
$-215 |
| 2011 |
$N/A |
| 2010 |
$N/A |
| 2009 |
$N/A |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$128.587B |
$44.458B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
